Dihydroergotamine mesylate intranasal - Novartis

Drug Profile

Dihydroergotamine mesylate intranasal - Novartis

Alternative Names: Dihydroergotamine mesylate nasal spray - Novartis; Dihydroergotamine-mesylate; Migranal

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 02 Jul 2013 Launched prior to this date for Migraine in Austria (Intranasal)
  • 02 Jul 2013 Launched prior to this date for Migraine in Canada (Intranasal)
  • 27 Jun 2013 Zogenix & Valeant Pharmaceuticals agree to co-promote dihydroergotamine mesylate nasal spray in USA for Migraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top